LeMaitre Vascular Inc. (NASDAQ:LMAT) was downgraded by analysts at Sidoti from a “buy” rating to a “neutral” rating in a report released on Thursday.

LMAT has been the subject of a number of other research reports. Brean Capital upped their target price on shares of LeMaitre Vascular from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Thursday, July 28th. Barrington Research boosted their price target on shares of LeMaitre Vascular from $18.50 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, July 28th. Canaccord Genuity set a $19.00 price target on shares of LeMaitre Vascular and gave the company a “buy” rating in a research report on Thursday, July 28th. Finally, Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $18.94.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT) traded down 5.23% on Thursday, reaching $20.49. 190,237 shares of the company traded hands. LeMaitre Vascular has a 1-year low of $11.80 and a 1-year high of $22.50. The stock has a 50 day moving average of $18.73 and a 200-day moving average of $15.92. The stock has a market capitalization of $378.33 million, a price-to-earnings ratio of 41.14 and a beta of 0.51.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/lemaitre-vascular-inc-lmat-stock-rating-lowered-by-sidoti.html

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, July 27th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.03. LeMaitre Vascular had a net margin of 11.43% and a return on equity of 11.90%. The business earned $22.40 million during the quarter, compared to analyst estimates of $21.59 million. The business’s revenue was up 12.6% compared to the same quarter last year. On average, equities analysts anticipate that LeMaitre Vascular will post $0.55 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Monday, August 22nd were given a $0.045 dividend. The ex-dividend date was Thursday, August 18th. This represents a $0.18 dividend on an annualized basis and a yield of 0.83%. LeMaitre Vascular’s payout ratio is currently 36.73%.

In other news, Chairman George W. Lemaitre sold 30,000 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $20.48, for a total transaction of $614,400.00. Following the sale, the chairman now owns 3,395,063 shares of the company’s stock, valued at $69,530,890.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David B. Roberts sold 6,452 shares of the stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $21.05, for a total transaction of $135,814.60. Following the sale, the insider now directly owns 69,793 shares in the company, valued at approximately $1,469,142.65. The disclosure for this sale can be found here. 28.90% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. American International Group Inc. boosted its stake in shares of LeMaitre Vascular by 11.7% in the second quarter. American International Group Inc. now owns 7,775 shares of the company’s stock valued at $111,000 after buying an additional 817 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of LeMaitre Vascular by 6.7% in the second quarter. Nationwide Fund Advisors now owns 9,293 shares of the company’s stock valued at $133,000 after buying an additional 580 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of LeMaitre Vascular by 19.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 11,330 shares of the company’s stock valued at $162,000 after buying an additional 1,826 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of LeMaitre Vascular during the first quarter valued at about $185,000. Finally, Greenleaf Trust acquired a new stake in shares of LeMaitre Vascular during the second quarter valued at about $210,000. 59.88% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

5 Day Chart for NASDAQ:LMAT

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.